FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics, namely to the use of an oral pharmaceutical composition and a method of treating a therapeutically effective amount of sodium aminodihydrophthalazinedione (ADPS). Use of an oral pharmaceutical composition for treating a disease selected from non-viral hepatitis, drug-induced hepatitis, containing: a. therapeutically effective amount of sodium aminodihydrophthalazinedione (ADPS) and b. pharmaceutically acceptable excipients. Method of treating a disease in a subject in need thereof, comprising administering orally to a subject in need thereof, a therapeutically effective dose of a pharmaceutical composition, where the disease is non-viral hepatitis or drug-induced hepatitis.
EFFECT: group of inventions described above allows treating non-viral or drug-induced hepatitis.
21 cl, 11 dwg, 20 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PROTECTION AGAINST CORONAVIRUS INFECTION | 2020 |
|
RU2747467C1 |
| COMBINED THERAPY WITH APPLICATION OF CENICRIVIROC FOR FIBROSIS TREATMENT | 2015 |
|
RU2723559C2 |
| PHARMACEUTICAL COMPOSITION OF OMEPRAZOL | 2012 |
|
RU2647472C2 |
| IBAT INHIBITOR FOR TREATING HEPATIC DISORDERS | 2011 |
|
RU2591188C2 |
| HEPATOPROTECTIVE AND ANTIHEPATOTOXIC PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATIC DISEASES THAT INVOLVES INTRODUCTION OF SAID COMPOSITION | 2008 |
|
RU2381800C1 |
| CYSTEAMINE DIOXYGENASE-RESISTANT ANALOGUES OF CYSTEAMINE AND THEIR USE | 2016 |
|
RU2766579C2 |
| DOSAGE FORM IN CAPSULE FORM CONTAINING TABLETS WITH DIMETHYL FUMARATE | 2019 |
|
RU2742745C1 |
| ORALLY ADMINISTERED PHARMACEUTICAL GRANULE OF EPIDERMAL GROWTH FACTOR | 2011 |
|
RU2540503C2 |
| ORAL RIFAMYCIN SV COMPOSITIONS | 2018 |
|
RU2793319C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
